Comprehensive dosing reference for GHK-Cu — covering topical concentrations and vehicles, subcutaneous injection protocols, reconstitution calculations, storage conditions, cycle lengths, and safety considerations. All information compiled from published literature and established research protocols.
Dosing information compiled from published literature and community protocols. Human clinical dosing is established primarily for topical use. Injectable protocols are derived from preclinical data and anecdotal research experience. For informational purposes only.
To reconstitute lyophilized GHK-Cu powder for subcutaneous injection, you will need: bacteriostatic water (BAC water, not sterile water — BAC water contains benzyl alcohol preservative to extend shelf life), insulin syringes (29–31G, 0.3–1 mL), alcohol swabs, and the lyophilized GHK-Cu vial. Verify the vial is sealed and the powder is white/off-white and dry before proceeding.
1. Swab the rubber stopper of the GHK-Cu vial and the BAC water vial with an alcohol swab. Allow to dry for 10 seconds.
2. Draw the desired volume of BAC water into your syringe. For a 5 mg vial, draw 2 mL of BAC water to achieve a concentration of 2.5 mg/mL (2,500 mcg/mL).
3. Inject the BAC water slowly into the GHK-Cu vial by directing the stream down the side of the glass (not onto the powder directly), to minimize foaming.
4. Gently swirl — do not shake — until the powder is fully dissolved. The solution should be clear to slightly blue-tinted (the copper chelate gives it a faint color).
5. Label the vial with the date of reconstitution. Store refrigerated (2–8°C). Use within 28 days.
100 mcg dose = 0.04 mL = 4 units on a U-100 insulin syringe
200 mcg dose = 0.08 mL = 8 units on a U-100 insulin syringe
300 mcg dose = 0.12 mL = 12 units on a U-100 insulin syringe
500 mcg dose = 0.20 mL = 20 units on a U-100 insulin syringe
If using a different vial size or BAC water volume, adjust accordingly: concentration (mcg/mL) = (vial mass in mcg) ÷ (BAC water volume in mL).
Subcutaneous injection sites include the abdomen (2 inches from the navel), outer thigh, and upper arm. Pinch the skin, insert the needle at a 45–90° angle, inject slowly, and withdraw. Rotate injection sites to avoid localized tissue irritation. GHK-Cu is generally well tolerated subcutaneously with minimal injection site reactions reported.
GHK-Cu has a long safety record in topical cosmetic applications and has been used in FDA-cleared wound dressings. Injectable safety data is more limited.
GHK-Cu is sold as a research compound and cosmetic ingredient. Injectable forms are not approved by the FDA or any regulatory agency for human therapeutic use. Topical GHK-Cu is used in cosmetic products and FDA-cleared wound dressings but is not classified as a drug. The information on this page is compiled from published peer-reviewed research and is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before making any health decisions.